United
States – Additional Tariff Measures on Goods from China
Request for Consultations by China
Addendum
The
following communication, dated 4 March 2025, from the delegation of China to
the delegation of the United States, is circulated to the Dispute Settlement
Body in accordance with Article 4.4 of the DSU.
_______________
1._
My
authorities have instructed me to request consultations with the Government of the United
States of America
pursuant to Articles
1 and 4 of the
Understanding on Rules and Procedures
Governing the Settlement of Disputes ("DSU"), and Article XXIII of the General Agreement on Tariffs and Trade 1994
("GATT
1994") with respect to the United States' measures
that increase the additional tariffs on goods originating in China from 10% to
20%. This addendum supplements and does not replace China's request for
consultations dated 4 February 2025[1].
I.
measures at issue
2._ Subsequent to the above mentioned request for
consultations, the United States issued the Executive Order[2] of 3 March 2025, which
amends the Executive Order[3] of 1 February 2025 and
increases the additional ad valorem tariffs imposed on all imported products originating in China from 10% and 20%. The
measures at issue are applied to products of Chinese origin only and are in
excess of the United States' bound rates in its Schedule of Concessions and
Commitments annexed to the GATT 1994. The measures at issue not only violate WTO rules, but are discriminatory and protectionist
in nature.
3._ The measures
at issue include, inter alia:
·_
Section 1702(a)(1)(B) of the International
Emergency Economic Powers Act;
·_
Fact Sheet: President Donald J. Trump Imposes Tariffs
on Imports from Canada, Mexico and China[4];
·_
Executive Order of 1 February 2025: Imposing Duties to
Address the Synthetic Opioid Supply Chain in the People's Republic of China;
·_
Federal Register notice described in section 2(d) of the Executive Order of 1
February 2025[5].
·_
Executive
Order of 3 March 2025: Further Amendment to Duties Addressing the
Synthetic Opioid Supply Chain in the People's Republic of China
4._ The
supplemental request
for consultations also includes any
amendments, supplements, or extensions to the measures specified above, as well
as any closely
connected, subsequent, replacement
or implementing measures.
_ II. legal basis of
the complaint
5._ The measures at
issue appear to be inconsistent with the United States' obligations under the following provisions of the
GATT 1994, including:
·_
Article I:1
of the GATT 1994, because the measures at issue fail to extend
immediately and unconditionally to China an "advantage, favour, privilege
or immunity" granted by the United States "[w]ith respect to
customs duties and charges of any kind imposed on or in connection with"
the importation of products originating in the territory of other Members.
·_
Article II:1(a) and (b) of the GATT 1994, because
the United States imposes additional tariffs on all imported products originating in China as identified in measures above
that are in excess of United States bound rates in its Schedule of Concessions
and Commitments annexed to the GATT 1994, and therefore fails
to accord to the
products originating in China and imported
into the United States treatment no less favourable than that provided for in
the United States' Schedule of Concessions and Commitments annexed to the GATT
1994.
6._ In
addition, and as a consequence of the foregoing, the measures at issue appear
to nullify or impair benefits accruing to China, directly or indirectly, under
the cited agreements.
7._ China
reserves the right to raise additional measures and claims regarding the
matters identified herein during the course of consultations and in any future
request for the establishment of a panel.
8._ China
looks forward to receiving the reply of the United States
to this request and to setting a mutually convenient date for consultations.
__________
[1] The request for consultations was circulated on 5 February 2025 in
document WT/DS633/1, G/L/1561.
[2] Executive Order of 3 March 2025, entitled Further Amendment to
Duties Addressing the Synthetic Opioid Supply Chain in the People's Republic of
China, see
https://www.whitehouse.gov/presidential-actions/2025/03/further-amendment-to-duties-addressing-the-synthetic-opioid-supply-chain-in-the-peoples-republic-of-china/.
[3] Executive Order of 1 February 2025, entitled Imposing Duties to
Address the Synthetic Opioid Supply Chain in the People's Republic of China,
see
https://www.whitehouse.gov/presidential-actions/2025/02/imposing-duties-to-address-the-synthetic-opioid-supply-chain-in-the-peoples-republic-of-china/.
[4] See
https://www.whitehouse.gov/fact-sheets/2025/02/fact-sheet-president-donald-j-trump-imposes-tariffs-on-imports-from-canada-mexico-and-china/.
[5] See
https://www.federalregister.gov/documents/2025/02/05/2025-02293/implementation-of-additional-duties-on-products-of-the-peoples-republic-of-china-pursuant-to-the.